IA
SPRO icon

IndexIQ Advisors’s Spero Therapeutics SPRO Stock Holding History

IndexIQ Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-28,689
Closed -$459K – 1489
2021
Q4 		$459K Sell
28,689
-1,854
-6% -$29.4K 0.02% 648
2021
Q3 		$562K Buy
30,543
+3,059
+11% +$49.1K 0.02% 477
2021
Q2 		$384K Sell
27,484
-1,984
-7% -$27.7K 0.01% 783
2021
Q1 		$434K Buy
+29,468
New +$519K 0.02% 418

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

IndexIQ Advisors's SPRO Position: Q1 2022 in Review

IndexIQ Advisors sold out of Spero Therapeutics (SPRO) in Q1 2022, closing a stake of 28,689 shares — an estimated $459K sold.

IndexIQ Advisors first reported a position in SPRO in Q1 2021 and held it in 4 quarters. The position peaked at $562K in Q3 2021. 100 funds tracked by Wall St. Rank hold SPRO as of Q1 2022.

  • IndexIQ Advisors reported no remaining Spero Therapeutics position as of Q1 2022 after selling out during the quarter.
  • IndexIQ Advisors sold 28,689 Spero Therapeutics shares in Q1 2022, an estimated $459K.
  • IndexIQ Advisors first reported a position in Spero Therapeutics in Q1 2021 and held it in 4 quarters.
  • IndexIQ Advisors's Spero Therapeutics position peaked at $562K in Q3 2021.
  • 100 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.